Jennifer Crombie, MD, Dana-Farber Cancer Institute, Boston, Massachusetts, discusses results from a real-world study of lisocabtagene maraleucel in patients with relapsed/refractory large B-cell lymphoma. Similar to published findings…
Tanya Siddiqi, MD, medical director of lymphoma, City of Hope, Orange County, California, discusses the primary analysis of the TRANSCEND CLL 004 trial. This phase 1/2, single-arm, multicenter…
In this video, Benjamin P. Levy, MD, assistant professor of oncology and clinical director of Medical Oncology for the Sidney Kimmel Cancer Center at Johns Hopkins Medicine, stresses…
Geoffrey Oxnard, MD, associate professor of medicine at Harvard Medical School, discusses the advancements in treatments for lung cancer over the past 10 to 15 years. Even though…
In an interview at the 18th British Thoracic Oncology Group (BTOG) 2020 congress, Sanjay Popat, BSc, MBBS, FRCP, PhD, of The Royal Marsden NHS Foundation Trust in London,…
Heather A. Wakelee, MD, thoracic oncologist and professor of medicine at Stanford University Medical Center, discusses the decisions that go into planning treatments for newly diagnosed, advanced stage…
Lyudmila A. Bazhenova, MD, professor of medicine at UC San Diego Health, discusses the lack of data on chemoimmunotherapy or monotherapy immunotherapy for treatment of ALK-fused non-small cell…
Ashish Saxena, MD, PhD, assistant attending at New York-Presbyterian Hospital and assistant professor of medicine at Weill Cornell Medical College, reviews first-line therapies in non-small cell lung cancer.…
Results from a cohort study suggest that vision loss, a common side effect after plaque radiotherapy for uveal melanoma, may be mitigated or avoided entirely thanks to prophylactic…
Rebecca L. Olin, MD, MSCE, associate professor in the Department of Medicine at the University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, discusses changes in…
The constantly evolving science and emerging study results focused on adjuvant therapies have drastically changed the treatment landscape for patients with melanoma. Along with targeted therapies, immunotherapies have…
The research team led by Alexander Eggermont, MD, PhD, of the Gustave Roussy Cancer Campus Grand Paris, found that among over 1,000 stage III patients with melanoma treated…
